CLEVELAND, Feb. 9, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that the University Hospital Halle (Saale) in Germany has purchased a MRIdian MRI-guided radiation therapy system for installation at the University Hospital´s Krukenberg Cancer Center, the academic provider of cancer services in Southern Saxony-Anhalt with specialized treatment drawing patients from adjacent states and nationally.

The Department of Radiation Oncology at University Hospital Halle (Saale), chaired by Prof. Dirk Vordermark, M.D., offers an extensive and long-standing stereotactic body radiotherapy (SBRT) program, focusing on early-stage lung cancer, primary hepatic tumors, and oligometastases. Prof. Vordermark and his colleagues plan to utilize MRIdian to offer SBRT treatments for abdominal and pelvic tumors including liver, pancreatic, prostate, gynecologic tumors, and central lung tumors.

"The MRIdian system offers exciting new opportunities to strengthen and extend the existing capacities to offer highly conformal hypofractionated stereotactic radiotherapy to patients from our region and beyond. We selected MRIdian for its unique offering of real-time tissue tracking, and automatic beam control and extensive clinical evidence," said Prof. Dr. Dirk Vordermark, Chairman of the Department of Radiation Oncology at University Hospital Halle (Saale).
"We are excited to welcome University Hospital Halle (Saale) to the global community of centers adopting MRIdian to offer personalized treatment to a broader population of cancer patients, including those who were previously considered untreatable," said Chief Medical Officer Martin Fuss, M.D, at ViewRay. "University Hospital Halle has a reputation for offering the most innovative treatment options available. The addition of MRIdian MRI-guided radiation therapy further advances their position as a leader in cancer care."

The MRIdian system provides oncologists outstanding anatomical visualization through diagnostic-quality MR images and the ability to adapt a radiation therapy plan to the targeted cancer with the patient on the table. This combination allows physicians to define tight treatment margins to avoid unnecessary radiation exposure of vulnerable organs-at-risk and healthy tissue and allows the delivery of ablative radiation doses in five or fewer treatment sessions, without relying on implanted markers. By providing real-time continuous tracking of the target and organs-at-risk, MRIdian enables automatic gating of the radiation beam if the target moves outside the user-defined margins. This allows for delivery of the prescribed dose to the target, while sparing surrounding healthy tissue and critical structures, which results in minimizing toxicities typically associated with conventional radiation therapy.

Nearly 18,000 patients have been treated with MRIdian. Currently, 48 MRIdian systems are installed at hospitals around the world where they are used to treat a wide variety of solid tumors and are the focus of numerous ongoing research efforts. MRIdian has been the subject of hundreds of peer-reviewed publications, scientific meeting abstracts, and presentations.


About ViewRay
ViewRay, Inc. (Nasdaq: VRAY) designs, manufactures, and markets the MRIdian® MRI-Guided Radiation Therapy System. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purpose-built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.


SOURCE ViewRay, Inc.

MRI Homepage